Joelle Helou

2.2k total citations
76 papers, 1.1k citations indexed

About

Joelle Helou is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, Joelle Helou has authored 76 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pulmonary and Respiratory Medicine, 38 papers in Radiation and 12 papers in Surgery. Recurrent topics in Joelle Helou's work include Prostate Cancer Diagnosis and Treatment (46 papers), Prostate Cancer Treatment and Research (42 papers) and Advanced Radiotherapy Techniques (38 papers). Joelle Helou is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (46 papers), Prostate Cancer Treatment and Research (42 papers) and Advanced Radiotherapy Techniques (38 papers). Joelle Helou collaborates with scholars based in Canada, United States and United Kingdom. Joelle Helou's co-authors include Andrew Loblaw, Ananth Ravi, Patrick Cheung, Hans T. Chung, Gerard Morton, Liying Zhang, Laura D’Alimonte, Alexandre Mamedov, William Chu and Andrea Deabreu and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Joelle Helou

72 papers receiving 1.1k citations

Peers

Countries citing papers authored by Joelle Helou

Since Specialization

Citations

This map shows the geographic impact of Joelle Helou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joelle Helou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joelle Helou more than expected).

Fields of papers citing papers by Joelle Helou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joelle Helou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joelle Helou. The network helps show where Joelle Helou may publish in the future.

Co-authorship network of co-authors of Joelle Helou

This figure shows the co-authorship network connecting the top 25 collaborators of Joelle Helou. A scholar is included among the top collaborators of Joelle Helou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joelle Helou. Joelle Helou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087) 2025 ·Radiotherapy and Oncology ·Gerard Morton, (unknown), Maroie Barkati, Joelle Helou, Tamim Niazi, John W. Robinson, D.A. Loblaw, (unknown), Hyun‐Tai Chung, Guila Delouya, Cynthia Ménard, Ángel G. Martín, Peter Chung, Deidre Batchelar, Michael Brundage, Kimberly Whelan, Keyue Ding, Wendy R. Parulekar	0
2	High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement 2025 ·Brachytherapy ·Sagar A. Patel, Marisa Kollmeier, Juanita Crook, Daniel Krauss, Gerard Morton, Albert J. Chang, Joelle Helou, I‐Chow Hsu, Cynthia Ménard, Shyamal Patel, Tyler P. Robin, Peter J. Rossi, Michael J. Zeléfsky, Mitchell Kamrava	0
3	The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Rachel Glicksman, Srinivas Raman, Xiang Y. Ye, Philippe L. Bédard, Scott V. Bratman, Eric X. Chen, Peter Chung, Laura A. Dawson, Andrew Hope, Ali Hosni, (unknown), Patricia Lindsay, Ciara O’Brien, Rebecca Wong, (unknown), Joelle Helou	4
4	Deep learning‐based ultrasound auto‐segmentation of the prostate with brachytherapy implanted needles 2023 ·Medical Physics ·(unknown), Thomas H. Harding, (unknown), (unknown), (unknown), Lucas C. Mendez, David D’Souza, Vikram Velker, Rohann Correa, Joelle Helou, (unknown), Aaron Fenster, Douglas A. Hoover	4
5	The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients With Oligometastatic Disease at 12 Months Post Stereotactic Body Radiation Therapy 2022 ·International Journal of Radiation OncologyBiologyPhysics ·Aisling Barry, Andrea Bezjak, Joelle Helou, Pamela J. Goodwin, Alex Kiss, Jolie Ringash, (unknown), (unknown), Patricia Lindsay, (unknown), (unknown), (unknown), Rebecca Wong	3
6	MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer 2022 ·Frontiers in Oncology ·Cynthia Ménard, (unknown), (unknown), Lisa Joseph, Maroie Barkati, Alejandro Berlín, Guila Delouya, Daniel Taussky, Marie-Claude Beauchemin, (unknown), Samuel Kadoury, Alexandra Rink, Srinivas Raman, (unknown), Robert Weersink, Dominic Béliveau‐Nadeau, Joelle Helou, Peter Chung	8
7	Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer 2021 ·Nature Medicine ·Chris McIntosh, Leigh Conroy, Michael C. Tjong, Tim Craig, Andrew Bayley, Charles Catton, Mary Gospodarowicz, Joelle Helou, (unknown), Victor Kong, Tony K.T. Lam, Srinivas Raman, Padraig Warde, Peter Chung, Alejandro Berlín, Thomas G. Purdie	114
8	Gantry-Based 5-Fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes From 2 Prospective Studies Comparing SABR Boost With MR Dose-Painted HDR Brachytherapy Boost 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Hima Bindu Musunuru, Patrick Cheung, Danny Vesprini, Stanley K. Liu, William Chu, Hans T. Chung, Gerard Morton, Andrea Deabreu, Melanie Davidson, Ananth Ravi, Joelle Helou, Ling Ho, Liying Zhang, Andrew Loblaw	3
9	Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging 2020 ·Advances in Radiation Oncology ·Wei Liu, Katherine Zukotynski, Louise Emmett, Hans T. Chung, Peter Chung, Robert J. Wolfson, Irina Rachinsky, Anil Kapoor, Ur Metser, Andrew Loblaw, Gerard Morton, Tracy Sexton, Michael Lock, Joelle Helou, Alejandro Berlín, Colm Boylan, (unknown), Gregory R. Pond, Glenn Bauman	12
10	Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience 2019 ·Brachytherapy ·Laura D’Alimonte, Ananth Ravi, Joelle Helou, David Morrison, Lucas C. Mendez, (unknown), Gerard Morton	16
11	Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials 2019 ·Clinical Oncology ·Soumyajit Roy, Andrew Loblaw, Patrick Cheung, William Chu, Hans T. Chung, Danny Vesprini, (unknown), Amrita Roy Chowdhury, Dilip Panjwani, Geordi Pang, (unknown), Melanie Davidson, Ananth Ravi, Boyd McCurdy, Joelle Helou, Liang Zhang, Alexandre Mamedov, Andrea Deabreu, Harvey Quon	4
12	MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial 2019 ·Radiotherapy and Oncology ·Yasir Alayed, Laura D’Alimonte, Joelle Helou, Ananth Ravi, Gerard Morton, Hans T. Chung, Masoom A. Haider, Merrylee McGuffin, Liying Zhang, Andrew Loblaw	24
13	Predictive factors for persistent and late radiation complications in breast cancer survivors 2019 ·Clinical & Translational Oncology ·(unknown), Tony Panzarella, Robert Dinniwell, Joelle Helou, W. Levin	6
14	Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials 2018 ·Radiotherapy and Oncology ·Yasir Alayed, Patrick Cheung, Geordi Pang, Alexandre Mamedov, Laura D’Alimonte, Andrea Deabreu, Kristina Commisso, (unknown), Liang Zhang, Harvey Quon, Hima Bindu Musunuru, Joelle Helou, D.A. Loblaw	41
15	Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis 2017 ·European Journal of Cancer ·Jacques Raphael, Joelle Helou, Kathleen I. Pritchard, David Naimark	30
16	Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost–Utility Analysis 2017 ·Clinical Oncology ·Joelle Helou, (unknown), Hima Bindu Musunuru, Jacques Raphael, Patrick Cheung, Danny Vesprini, Hans T. Chung, Laura D’Alimonte, Murray Krahn, Gerard Morton, Andrew Loblaw	11
17	Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose? 2017 ·Radiotherapy and Oncology ·Joelle Helou, Laura D’Alimonte, Harvey Quon, Andrea Deabreu, Kristina Commisso, Patrick Cheung, William Chu, Alexandre Mamedov, Melanie Davidson, Ananth Ravi, Andrew Loblaw	25
18	Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Joelle Helou, Isabelle Thibault, Ian Poon, Andrew Chiang, Suneil Jain, Hany Soliman, Darby Erler, Latifa Yeung, Patrick Cheung	54
19	Quantifying Health Utilities in Patients Undergoing Stereotactic Body Radiation Treatment for Liver Metastases for Use in Future Economic Evaluations 2017 ·Clinical Oncology ·(unknown), (unknown), Kelvin Chan, William Chu, Joelle Helou, Darby Erler, Hans T. Chung	4
20	Tomothérapie hélicoïdale dans le traitement du mésothéliome pleural malin : impact des faibles doses sur la toxicité pulmonaire et œsophagienne 2013 ·Cancer/Radiothérapie ·Joelle Helou, (unknown), (unknown), L. Campion, (unknown), S. Zefkili, Jacques Raphael, P. Bonnette, Françoise Le Pimpec‐Barthes, Christian Périgaud, Marc-André Mahé, P. Giraud	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact